These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2672013)

  • 1. The experience with intravesical BCG-immunotherapy in the management of superficial bladder cancer in the United Kingdom.
    Robinson MR
    Prog Clin Biol Res; 1989; 310():147-51. PubMed ID: 2672013
    [No Abstract]   [Full Text] [Related]  

  • 2. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 3. [Intravesical immunotherapy with BCG vaccine in superficial carcinoma of the urinary bladder].
    Pacík D; Vít V; Turjanica M
    Rozhl Chir; 1997 Oct; 76(10):482-5. PubMed ID: 9471737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCG in bladder cancer.
    Meek D
    Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
    van der Meijden PM; Debruyne FM; Steerenberg PA; de Jong WH; Doesburg W
    Prog Clin Biol Res; 1989; 310():285-98. PubMed ID: 2505272
    [No Abstract]   [Full Text] [Related]  

  • 7. BCG vaccine therapy for treatment of superficial bladder cancer.
    Damianov C; Patrashkov T; Tonchev T; Engibarov A; Kasabov V; Chouchkova M
    Int Urol Nephrol; 1989; 21(3):305-12. PubMed ID: 2807782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravesical bacillus Calmette-Guérin (BCG) in superficial bladder tumors. An overview.
    Debruyne FM; Witjes JA; vd Meijden AP
    Arch Esp Urol; 1990; 43 Suppl 2():133-8. PubMed ID: 2096774
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effect of intravesical bacillus Calmette-Guérin (BCG) Tice strain on flat carcinoma in situ of the bladder.
    Reitsma DJ; Guinan P; Lamm DL; Khanna OP; Brosma SA; DeKernion JB; Williams RD; Sipmson G; Hanna MG
    Prog Clin Biol Res; 1989; 310():171-85. PubMed ID: 2672014
    [No Abstract]   [Full Text] [Related]  

  • 10. [Granulomatous hepatitis following intravesical BCG immunotherapy for cancer of the bladder].
    Gargot D; Alexandre L; Sinico M; Salmeron S; Benoit G; Buffet C
    Gastroenterol Clin Biol; 1991; 15(8-9):662-3. PubMed ID: 1752384
    [No Abstract]   [Full Text] [Related]  

  • 11. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
    Rintala E; Jauhiainen K; Alfthan O
    Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
    [No Abstract]   [Full Text] [Related]  

  • 12. Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action.
    Catalona WJ; Ratliff TL
    Surg Annu; 1990; 22():363-78. PubMed ID: 2408170
    [No Abstract]   [Full Text] [Related]  

  • 13. [Granulomatous prostatitis after intravesical BCG immunotherapy of superficial bladder cancer: a case report].
    Sai S; Sakakibara T; Takashi M; Sakata T; Miyake K
    Hinyokika Kiyo; 1990 Aug; 36(8):953-5. PubMed ID: 2239600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study of the BCG Tokyo strain for intravesical treatment in patients with superficial bladder cancer. BCG Study Group.
    Aso Y; Akaza H; Kameyama S; Niijima T
    Prog Clin Biol Res; 1989; 303():383-91. PubMed ID: 2675000
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravesical therapy for superficial bladder cancer.
    Malkowicz SB
    Semin Urol Oncol; 2000 Nov; 18(4):280-8. PubMed ID: 11101091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review.
    Talug C; Brown ET; Zaslau S; Kandzari SJ
    W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033
    [No Abstract]   [Full Text] [Related]  

  • 17. BCG versus cytotoxic chemotherapy in the treatment of superficial bladder tumors.
    Boccon-Gibod L
    Prog Clin Biol Res; 1992; 378():55-7. PubMed ID: 1301586
    [No Abstract]   [Full Text] [Related]  

  • 18. Intravesical BCG therapy in patients with superficial bladder tumors.
    Steg A; Belas M; Leleu C; Boccon-Gibod L
    Prog Clin Biol Res; 1989; 310():153-60. PubMed ID: 2771990
    [No Abstract]   [Full Text] [Related]  

  • 19. BCG-RIVM intravesical immunoprophylaxis for superficial bladder cancer.
    Debruyne FM; van der Meijden AP; Schreinemachers LM; Geboers AD; Franssen MP; van Leeuwen MJ; Steerenberg PA; de Jong WH; Ruitenberg EJ
    Prog Clin Biol Res; 1988; 269():511-24. PubMed ID: 3134662
    [No Abstract]   [Full Text] [Related]  

  • 20. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
    van der Meijden AP
    Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.